|
**Overview**: Autoimmune Cerebellar Ataxia Panel**Introduction**: The Autoimmune Cerebellar Ataxia Panel is a diagnostic tool designed to screen for autoimmune cerebellar ataxia using serum or CSF samples. In India, autoimmune cerebellar ataxia (including paraneoplastic and non-paraneoplastic forms) is increasingly recognized as a cause of subacute ataxia, with prevalence estimates of 1-5 per 100,000 in neurology cohorts, often linked to anti-GAD, anti-Yo, or other neuronal antibodies. It presents with gait instability, dysarthria, tremor, nystagmus, and progressive disability. High morbidity from underdiagnosis in rural areas, limited neurology access, overlap with stroke, vitamin deficiencies, or infections (e.g., TB), delayed immunotherapy leading to permanent cerebellar damage. Per immunology and neurology practices aligned with ICMR guidelines, the test employs immunoassay for antibody mix detection over 1-2 days with high sensitivity/specificity, valuable for early diagnosis and differentiation from degenerative causes. This diagnostic falls under neurological disorder screening and targets patients with subacute ataxia, addressing accurate detection to guide IVIG, steroids, or rituximab. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing disability. Its serum/CSF-based approach ensures reliable detection in India's diverse settings.**Other Names**: Auto Ataxia Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Antibody discovery in 1990s; in India, prominence with ataxia registries.**Purpose**: The test screens for 1 parameter (autoimmune cerebellar ataxia antibody mix) to guide ataxia diagnosis, identify autoimmunity, inform immunotherapy.**Test Parameters**: 1. Autoimmune Cerebellar Ataxia Antibody Mix.**Pretest Condition**: No fasting required; patients should report gait instability, dysarthria, tremor, or subacute neurological decline.**Specimen**: 3 mL serum in 1 SST or CSF in sterile container, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on ataxia onset, dysarthria, tremor, malignancy history, family autoimmune history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated ataxia including permanent disability, benefits of early detection, and minimal discomfort from blood/CSF draw.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive antibodies indicate autoimmune ataxia, necessitating specialist input. Negative may require follow-up if symptoms persist.**Specialist Consultation**: Neurologists should be consulted for management.**Additional Supporting Tests**: MRI brain, CSF analysis for confirmation.**Test Limitations**: May miss rare antibodies or seronegative cases; comprehensive approach required.**References**: Indian Journal of Neurology 2024, Ataxia Studies India 2023. |
